Chemical Information
Antiviral agent ID	DrugRepV_3563
Antiviral agent name	IFN-alpha2a
Common Name	Interferon alfa-n1
Synonyms	Interferon alpha-2 | Interferon alpha-A | Interferon alpha-n1 (Ins) | LeIF A
Structural Information
2-D Structure is not available	3-D Structure is not available
Clinical Information
Category	Antineoplastic and Immunomodulating Agentss
Primary Indication (Clinical trial phases)	Approved, Investigational
Biological Information
Primary Indication (Disease Category)	Infectious and Non Infectious Disease
Primary Indication (Disease)	Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia
Secondary Indication	Chikungunya virus (CHIKV) NA 181/clone 25
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	Vero
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	0.0001 MOI
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Post infection
Secondary Indication (Duration of drug delivery)	3 days
Secondary Indication (Drug concentration)	1344.6 μM
Secondary Indication (Cell based assay)	Plaque assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Secondary Indication (Cytotoxicity)	>10,000 μM
Reference	Franco EJ, Rodriquez JL, Pomeroy JJ, Hanrahan KC, Brown AN.The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies.Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618807580. doi: 10.1177 /2040206618807580 PMID:30354193
Comment	Favipiravir and interferon-alfa are the most promising candidates, as their use led to substantial reductions in viral burden at clinically achievable concentrations in two human-derived cell lines.